SEARCH

SEARCH BY CITATION

References

  • Abu-Amara M, Yang SY, Tapuria N, Fuller B, Davidson B, Seifalian A (2010). Liver ischemia/reperfusion injury: processes in inflammatory networks – a review. Liver Transpl 16: 10161032.
  • Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY et al. (2000). The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 165: 52695277.
  • Ahuja SK, Murphy PM (1996). The CXC chemokines growth-related oncogene (Gro)alpha, GRO beta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 271: 2054520550.
  • Allegretti M, Bertini R, Bizzarri C, Beccari AR, Mantovani M, Locati M (2008). Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharmacol Sci 29: 280286.
  • Baggiolini M, Loetscher P (2000). Chemokines in inflammation and immunity. Immunol Today 21: 418420.
  • Barcelos LS, Talvani A, Teixeira AS, Vieira LQ, Cassali GD, Andrade SP et al. (2005). Impaired inflammatory angiogenesis, but not leukocyte influx, in mice lacking TNFR1. J Leukoc Biol 78: 352358.
  • Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G et al. (2004). Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 101: 1179111796.
  • Bizzarri C, Bertini R, Bossù P, Sozzani S, Mantovani A, Van Damme J et al. (1995). Single-cell analysis of macrophages chemotactic protein-1-regulated cytosolic Ca2+ increase in human adherent monocytes. Blood 86: 23882394.
  • Bizzarri C, Allegretti M, Di Bitondo R, Cervellera MN, Colotta F, Bertini R (2003). Pharmacological inhibition of intereleukin-8 (IL-8) as a new approach for the prevention and treatment of several human diseases. Curr Med Chem-Anti-Inflammatory and Anti-Allergy. Agents 2: 6779.
  • Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M (2006). ELR+ CXCR chemokines and their receptor (CXC chemokine rceptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 112: 139149.
  • Boyle JEM, Kovacich JC, Hebert CA, Canty JTG, Chi E, Morgan EN et al. (1998). Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. J Thorac Cardiovasc Surg 116: 114121.
  • Brandolini L, Allegretti M, Colagioia S, Novellini R, Colotta F, Bertini R (2004). Update on current and future pharmacologic therapy in COPD. Curr Med Chem Anti Inflamm Anti Allergy Agents 3: 81101.
  • Casilli F, Bianchini A, Gloaguen I, Biordi L, Alesse E, Festuccia C et al. (2005). Inhibition of interleukin-8 (IL-8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem Pharmacol 69: 385394.
  • Cassatella M, Gasperini S, Calzetti F, Bertagnin A, Luster AD, McDonald P (1997). Regulated production of the interferon-γ-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol 27: 111115.
  • Cavalieri B, Mosca M, Ramadori P, Perrelli MG, De Simone F, Colotta F et al. (2005). Neutrophil recruitment in the reperfused-injured rat liver was effectively attenuated by repertaxin, a novel allosteric non-competitive inhibitor of CXCL8 receptors: a therapeutic approach for the treatment of post-ischemic hepatic syndromes. Int J Immunopathol Pharmacol 18: 475486.
  • Coelho FM, Pinho V, Amaral FA, Sachs D, Costa VV, Rodrigues DH et al. (2008). The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. Arthritis Rheum 58: 23292337.
  • Crowther M, Brown NJ, Bishop ET, Lewis CE (2001). Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 70: 478490.
  • Cugini D, Azzolini N, Gagliardini E, Cassis P, Bertini R, Colotta F et al. (2005). Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 67: 17531761.
  • Cutrin JC, Boveris A, Zingaro B, Corvetti G, Poli G (2000). In situ determination by surface chemiluminescence of temporal relationships between evolving warm ischemia-reperfusion injury in rat liver phagocyte activation and recruitment. Hepatology 31: 622632.
  • Cutrin JC, Perrelli MG, Cavalieri B, Peralta C, Rosell Catafau J, Poli G (2002). Microvascular dysfunction induced by reperfusion injury and protective effect of ischemic preconditioning. Free Radic Biol Med 33: 12001208.
  • Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009). Monocyte chemoattractant protein-1: an overview. J Interferon Cytokine Res 29: 313326.
  • Devalaraja RM, Nanney LB, Du J, Qian Q, Yu Y, Devalaraja MN et al. (2000). Delayed wound healing in CXCR2 knockout mice. J Invest Dermatol 115: 234244.
  • Di Cioccio V, Strippoli R, Bizzarri C, Troiani G, Cervellera MN, Gloaguen I et al. (2004). Key role of proline-rich tyrosine kinase 2 in interleukin-8 (IL-8/IL-8)-mediated human neutrophil chemotaxis. Immunology 111: 407415.
  • Edgar RC (2004). MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 5: 113.
  • El-Sawy T, Belperio JA, Strieter RM, Remick DG, Fairchild RL (2005). Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 112: 320331.
  • Ferreira MA, Barcelos LS, Campos PP, Vasconcelos AC, Teixeira MM, Andrade SP (2004). Sponge-induced angiogenesis and inflammation in PAF receptor-deficient mice (PAFR-KO). Br J Pharmacol 141: 11851192.
  • Freitas MC, Uchida Y, Zhao D, Ke B, Busuttil RW, Kupiec-Weglinski JW (2010). Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transpl 16: 600610.
  • Garau A, Bertini R, Colotta F, Casilli F, Bigini P, Cagnotto A et al. (2005). Neuroprotection with the IL-8 inhibitor repertaxin in transient brain ischemia. Cytokine 30: 125131.
  • Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S et al. (2006). Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat. Eur Cytokine Netw 17: 3541.
  • Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M et al. (2001). The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 108: 13071314.
  • Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R et al. (1998). Macrophage derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem 273: 17641768.
  • Kasama T, Kobayashi K, Yajima N, Shiozawa F, Yoda Y, Takeuchi HT et al. (2000). Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis. Clin Exp Immunol 121: 533538.
  • Kuboki S, Shin T, Huber N, Eismann T, Galloway E, Schuster R et al. (2008). Hepatocyte signalling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice. Hepatology 48: 12131223.
  • Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK (2005). Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8: 6371.
  • Lu CY (1996). Ischemia, injury, and renal allograft rejection. Curr Opin Nephrol Hypertens 5: 107110.
  • McCourt M, Wang JH, Sookhai S, Redmond HP (1999). Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 134: 13251331.
  • McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CCM et al. (2010). Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330: 362366.
  • McLaren M, Newton DJ, Khan F, Belch JJ (2002). Vascular endothelial growth factor in patients with critical limb ischemia before and after amputation. Int Angiol 21: 165168.
  • Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL (2009). Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 41: 9981001.
  • Miura M, Fu X, Zhang QW, Remick DG, Fairchild RL (2001). Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. Am J Pathol 159: 21372145.
  • Molesworth-Kenyon SJ, Oakes JE, Lausch RN (2005). A novel role for neutrophils as a source of T cell-recruiting chemokines IP-10 and Mig during the DTH response to HSV-1 antigen. J Leukoc Biol 77: 552559.
  • Moloney WC, McPherson K, Fliegelman L (1960). Esterase activity in leukocytes demonstrated by the use of naphthol AS-D chloroacetate substrate. J Histochem Cytochem 8: 200207.
  • Moriconi A, Cesta MC, Cervellera MN, Aramini A, Colagioia S, Beccari AR et al. (2007). Rational design of non-competitive and dual inhibitors of interleukin-8 (IL-8) receptors. J Med Chem 50: 39844002.
  • Morita K, Miura M, Paolone DR, Engeman TM, Kapoor A, Remick DG et al. (2001). Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection. J Immunol 167: 29792984.
  • Munson PJ, Rodbard D (1980). Ligand: a versatile computerized approach for characterization of ligand-binding system. Anal Biochem 107: 220239.
  • Pine JK, Aldouri A, Young AL, Davies MH, Attia M, Toogood GJ et al. (2009). Liver transplantation following donation after cardiac death: an analysis using matched pairs. Liver Transpl 15: 10721082.
  • Rand ML, Warren JS, Mansour MK, Newman W, Ringler DJ (1996). Inhibition of T cell recruitment and cutaneous delayed-type hypersensitivity-induced inflammation with antibodies to monocyte chemoattractant protein-1. Am J Pathol 148: 855864.
  • Robertson MJ (2002). Role of chemokines in the biology of natural killer cells. J Leukoc Biol 71: 173183.
  • Russo RC, Guabiraba R, Garcia CC, Barcelos LS, Roffê E, Souza AL et al. (2009). Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 40: 410421.
  • Russo RC, Garcia CC, Teixeira MM (2010). Anti-inflammatory drug development: broad or specific chemokine receptor antagonists? Curr Opin Drug Discov Devel 13: 414427.
  • Sahni A, Francis CW (2000). Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 96: 37723778.
  • Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K (1993). Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 365: 654: 657.
  • Shaw JP, Chuang N, Yee H, Shamamian P (2003). Polymorphonuclear neutrophils promote rFGF-2-induced angiogenesis in vivo. J Surg Res 109: 3742.
  • Shoskes DA, Halloran PF (1996). Delayed graft function in renal transplantation: etiology, management and log-term significance. J Urol 155: 18311840.
  • Shoskes DA, Shahed AR, Kim S (2001). Delayed graft function. Influence on outcome and strategies for prevention. Urol Clin North Am 28: 721732.
  • Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R et al. (2009). Small-molecule antagonists for CXCR1 and CXCR2 inhibit human melanoma growth by decreasing tumor cell proliferation, survival and angiogenesis. Clin Cancer Res 15: 23802386.
  • Smith ML, Olson TS, Ley K (2004). CXCR2- and E-selectin-induced neutrophil arrest during inflammation in vivo. J Exp Med 200: 935939.
  • Soehnlein O, Lindbom L (2010). Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10: 427439.
  • Souza DG, Bertini R, Vieira AT, Cunha FQ, Poole S, Allegretti M et al. (2004). Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 143: 132142.
  • Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP (2005). CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 16: 593609.
  • Take F, Luedde T, Trautwein C (2009). Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 36: 412.
  • Tani K, Su SB, Utsunomiya I, Oppenheim JJ, Wang JM (1998). Interferon-gamma maintains the binding and functional capacity of receptors for IL-8 on cultured human T cells. Eur J Immunol 28: 502507.
  • Theilgaard-Mönch K, Knudsen S, Follin P, Borregaard N (2004). The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J Immunol 172: 76847693.
  • Traves SL, Smith SJ, Barnes PJ, Donnelly LE (2004). Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 76: 441450.
  • Tsuchihashi S, Ke B, Kaldas F, Flynn E, Busuttil RW, Briscoe DM et al. (2006). Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse liver against ischemia/reperfusion injury. Am J Pathol 168: 695705.
  • Tsuruma T, Yagihashi A, Tarumi K, Hirata K (1998). Anti-rat IL-8(CINC) monoclonal antibody administration reduces ischemia-reperfusion injury in small intestine. Transplant Proc 30: 26442645.
  • Wise EL, Duchesnes C, da Fonseca PC, Allen RA, Williams TJ et al. (2007). Small molecule receptor agonist and antagonist of CXCR3 provide insight into mechanism of chemokine receptor activation. J Biol Chem 282: 2793527943.
  • Yoshimura T, Takahashi M (2007). IFN-γ-mediated survival enables human neutrophils to produce MCP-1/CCL2 in response to activation by TLR ligands. J Immunol 179: 19421949.
  • Zaja-Milatovic S, Richmond A (2008). CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol Histopathol 23: 13991407.